J&J, TALisman Phase 2 Trial Validates Talvey's Taste Disorder Prevention Strategy
Clinical Design and Key Objectives
Janssen Research & Development, a subsidiary of Johnson & Johnson (JNJ), is conducting the TALisman Phase 2 trial (NCT06500884) with 210 patients with multiple myeloma. This open-label, randomized study began on August 26, 2024, is ongoing with recruitment expected to continue until June 2026, and the primary completion date is set for May 30, 2030. Talvey (talquetamab-tgvs), marketed under this brand, is a bispecific antibody targeting GPRC5D and CD3. The trial compares four prevention strategies to reduce the incidence, severity, and duration of taste disorders. A separate cohort evaluates ramantamig (JNJ-79635322), a trispecific antibody targeting BCMA, GPRC5D, and CD3.
Oral Toxicity Limiting Commercialization
In the MonumenTAL-1 safety cohort of 339 patients included in the FDA-approved label, taste disorders were reported in 70% of Talvey-treated patients, dry mouth in 34%, and weight loss in 35%. TALisman uses the Waterless Empirical Taste Test (WETT) to objectively assess taste disorders, aiming to bring the normative group to below the 25th percentile and severe cases to below the 10th percentile. The study also measures improvements at 3 and 7 months and tracks treatment discontinuation. Even if efficacy is maintained, deterioration in food intake, weight, and treatment adherence can shorten the actual duration of therapy. If the prevention strategies prove effective, they could convert the mechanistic toxicity of GPRC5D targeting into a manageable cost, thereby enhancing Talvey's clinical value and prescription retention.
Regulatory Basis and Competitive Landscape
The FDA granted Talvey accelerated approval on August 9, 2023, for the treatment of relapsed or refractory multiple myeloma in patients who have received four or more prior therapies. The EMA granted conditional approval on August 21, 2023, for patients who have received three or more prior therapies. In Japan, the Ministry of Health, Labour and Welfare approved Talvey on June 24, 2025, for patients with relapsed or refractory disease for whom standard therapy is difficult. The PMDA review concluded approval was likely on June 6, 2025, with risk management conditions specified. Competitors include bispecific antibodies Tecvayli (teclistamab-cqyv), Elrexfio (elranatamab-bcmm), Lynozyfic (linvoseltamab-gcpt), and BCMA CAR-T therapies Carvykti (ciltacabtagene autoleucel) and Abecma (idecabtagene vicleucel). While Talvey has a target differentiation as the first approved GPRC5D×CD3 therapy, oral, skin, and nail toxicity remain key variables in competitive selection.
Market and Development Strategy Implications
The global multiple myeloma treatment market is projected to grow from USD 29.24 billion in 2025 to USD 49.79 billion in 2034. In this market, prevention strategies do not create new anti-cancer effects but instead improve treatment persistence and patient experience for lifecycle management of already approved assets. The ramantamig cohort is significant for its simultaneous targeting of BCMA and GPRC5D, addressing antigen loss and tumor heterogeneity while also quantifying GPRC5D-related oral toxicity. Therefore, the success or failure of this study directly impacts not only the defense of Talvey's sales but also the safety profile required for J&J to expand next-generation multi-specific antibodies into earlier lines of therapy.
In the short term, the TALisman Phase 2 trial will verify whether prevention strategies can reduce taste disorders observed in 70% of Talvey-treated patients, and will provide evidence to differentiate prescription competitiveness through data on treatment discontinuation, weight loss, and quality of life. From an investment perspective, Johnson & Johnson (JNJ)'s ability to manage the unique toxicity of GPRC5D will influence product differentiation and treatment duration in the USD 29.24 billion multiple myeloma market in 2025, as it competes with Tecvayli, Elrexfio, Lynozyfic, and CAR-T therapies. For researchers, WETT-based quantitative taste evaluation and the ramantamig Phase 2 cohort will provide data to interpret the efficacy and mechanistic toxicity of GPRC5D, BCMA, and CD3 trispecific therapy. In the medium to long term, an effective prevention strategy will enhance the real-world value of Talvey, which has secured FDA accelerated approval, EMA conditional approval, and Japanese approval, and will act as a catalyst to reduce the risk in J&J's next-generation multi-specific antibody development.
Source: ClinicalTrials.gov (api_ct)